Quanta’s SC+ HFT results published in Hemodialysis International
Category: #health  By Mateen Dalal  Date: 2019-04-15
  • share
  • Twitter
  • Facebook
  • LinkedIn

Quanta’s SC+ HFT results published in Hemodialysis International

The results from the SC+ HFT with patients as well as healthcare professionals prove that SC+ is easy to use even with a significant learning decay period and minimal training.

UK-based medical technology company Quanta Dialysis Technologies Ltd., has apparently declared THAT the results from its HFT (human factors testing) of SC+ have been published in a leading peer-reviewed journal for the renal community, titled Hemodialysis International.

For the uninitiated, SC+ had been designed to make home hemodialysis and self-care accessible to patients via a small, easy-to-use device that is strong enough to deliver dialysis adequacy, thereby helping patients undertake control of their lives. The device also fulfils the requirement of a dialysis system that patients not only find appealing but it is also suitable to be used across clinics and homes.

As per sources familiar with the knowledge of the matter, the HFT of SC+ had been performed with 17 medical care professionals comprising healthcare assistants and nephrology nurses, and 15 home users including caregivers and patients.  The HFT had been undertaken in an effort to analyze if SC+ could be used effectively and safely.

Apparently, the HFT involved 4.5 to 6 hours of training, and post a training decay period of a minimum of 24 hours, a subsequent test session was undertaken wherein participants were scrutinized independently performing tasks on SC+. Only 29 use errors were observed out of the 1,216 opportunities for error, between these two user groups, despite minimal training. Also, reports claim that the errors that occurred had been minor and had been attributed to the initial lack of device familiarity rather than device safety.

John E. Milad, CEO, Quanta Dialysis Technologies, has been quoted to say that the device uptake rates are low despite the benefits that the home haemodialysis offers. The low uptake may also be related to the fear concerned with self-managing treatments at home, continues Milad. Nonetheless, SC+ is a patient-centric, user-friendly, personal hemodialysis system, Milad says, adding that the findings in this study lend a strong support to the company’s claims that it is capable enough to address systemic and patient barriers, and to enable enhanced self-care.

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

Ambrx partners with Bristol-Meyers to initiate Relaxin clinical trial
Ambrx partners with Bristol-Meyers to initiate Relaxin clinical trial
By Mateen Dalal

Ambrx will receive additional development payments with Bristol-Meyers’ initiation of the Phase 1 clinical trial for Relaxin Ambrx Inc., a biopharmaceutical company focused on developing protein therapeutics, has recently announced that Bristo...

LifeSpan Bio acquires Everest Biotech to expand reagent portfolio
LifeSpan Bio acquires Everest Biotech to expand reagent portfolio
By Mateen Dalal

The transaction will be LifeSpan BioSciences’ second investment this year following its Nordic-MUbio acquisition LifeSpan BioSciences (LSBio), a provider of life science research reagents and antibodies, has recently announced that it has acqu...

AbbVie buys Mavupharma to target STING pathway for cancer treatment
AbbVie buys Mavupharma to target STING pathway for cancer treatment
By Mateen Dalal

AbbVie Inc., a US-based pharmaceutical company recently announced acquisition of Mavupharma, a Seattle-based biopharmaceutical company, which is focused on innovative strategies to target the STimulator of INterferon Genes pathway for the treatment o...